Browse the evidence

Tirzepatide was evaluated for its effects on cardiovascular and diabetic kidney disease biomarkers in overweight and obese adults with type 1 diabetes over a period of 21 months.

Practitioners may consider tirzepatide for managing cardiovascular and kidney health in overweight and obese patients with type 1 diabetes.

All exercise bouts increased mRNA expression of MYOD1 and MYF6 over time.

Engaging in exercise can enhance the expression of key myogenic factors involved in muscle growth.

Several of the observed protein associations were also linked to prevalent obesity in the Framingham Heart Study.

Understanding these associations may inform obesity prevention strategies.

CLA supplementation altered 57 metabolites enriched in lipids/lipid-like molecules compared to placebo.

CLA supplementation may lead to significant changes in lipid metabolism.

Fifteen distinct gene clusters are regulated by disuse and connected to muscle mass or MPS changes.

Understanding these gene clusters may help in developing interventions to mitigate muscle loss during disuse.

3-methylhistidine and proline betaine concentrations increased consistently when participants were assigned a Prudent diet (q < 0.05) in both plasma and urine samples.

Practitioners can use these metabolites as biomarkers to monitor adherence to a Prudent diet.

Creatinine-normalized urinary imidazole propionate, hydroxypipecolic acid, dihydroxybenzoic acid, and enterolactone glucuronide increased with a Prudent diet (p < 0.05).

These metabolites can serve as indicators for dietary adherence to a Prudent diet.

Long-acting GLP-1 pharmacological agents have been approved for the treatment of obesity.

Practitioners can consider long-acting GLP-1 agents as viable options for obesity management.

Macronutrients and micronutrients influence cardiovascular disease (CVD).

Nutritional recommendations for CVD prevention should include a focus on both macronutrients and micronutrients.

Obesity is linked to increased cancer susceptibility and adverse prognostic outcomes.

Awareness of obesity's impact on cancer outcomes is essential for patient management.

Coconut milk supplementation induced beneficial changes in the lipid profile, decreasing LDL and non-HDL levels while increasing HDL levels.

Incorporating coconut milk into the diet may improve lipid profiles, particularly for individuals with elevated LDL levels.

The subgroup with elevated baseline LDL levels benefited most from coconut milk supplementation.

Individuals with high LDL levels may see greater improvements in their lipid profiles by consuming coconut milk.

The MC4R rs17782313 polymorphism has positive effects on dietary glycemic index (GI) and glycemic load (GL) (B = 1.577; P ≤ 0.01 for GI; B = 1.235; P ≤ 0.01 for GL).

Understanding the genetic basis of GI and GL can inform dietary recommendations for obesity management.

Both IF and KD enhance insulin sensitivity, promote autophagy, reduce inflammation, and activate energy-regulating pathways (AMPK) while inhibiting mTOR.

Understanding these mechanisms can help practitioners explain the benefits of IF and KD to patients.

Higher ultraprocessed grain intake is associated with increased risk of developing inflammatory bowel disease (IBD), with participants consuming ≥19 g/d having a hazard ratio (HR) of 1.86 compared to those consuming <9 g/d.

Practitioners should advise minimizing ultraprocessed grain consumption to reduce IBD risk.

Participants with greater ultraprocessed food intake (≥5 servings per day) are linked to a higher risk of developing IBD, with a hazard ratio of 3.95 compared to those consuming <1 serving per day.

Reducing ultraprocessed food intake may lower the risk of IBD.

Ribosomal biogenesis regulates the dose-response relationship between training volume and muscle hypertrophy.

Understanding the role of ribosomal biogenesis can help optimize resistance training protocols for hypertrophy.

The differences in MPS rates between whey and soy protein may be due to higher leucine content and more rapid leucinemia with whey.

Understanding the role of leucine may help in selecting protein sources for muscle health in the elderly.

The FDA has conditionally approved Resmetirom as the first pharmacological treatment for MASH.

Clinicians should consider Resmetirom as a treatment option for MASH.

Recent innovations in bariatric research include pharmacological therapies targeting GLP-1 receptors, minimally invasive procedures, and genetic and microbiome-based strategies.

These innovations may provide new options for obesity treatment.

Pharmacoeconomic analyses support the cost-effectiveness of combining behavioral, pharmacological, and surgical modalities for obesity treatment.

Integrating various treatment modalities can enhance cost-effectiveness in obesity management.

Obesity management requires understanding both genetic and environmental components.

Practitioners should consider both genetic and lifestyle factors in obesity treatment.

Lifestyle interventions can help in the prevention and treatment of obesity by altering epigenetic signatures.

Encouraging lifestyle changes can be an effective strategy in obesity treatment.

Interactions between the genetic risk score and dietary factors, specifically trans fats, were observed, indicating that the effects of trans fats on CHD risk are more pronounced in individuals with a higher genetic risk score.

Understanding the interaction between genetics and diet can help tailor dietary recommendations for individuals at higher genetic risk for CHD.